These findings suggest that—as a part of a panel—CDH16 immunohistochemistry might assist the identification of papillary thyroid cancer, the distinction of renal cell carcinomas from other neoplasms in cases of uncertain tumor origin, and the diagnosis of a nephrogenic adenoma. This evidence concerns the gene CDH16 and thyroid gland papillary carcinoma.